Benign prostatic hyperplasia/urinary retention:
Indications for PROSCAR:
BPH, to improve symptoms and reduce risks of acute urinary retention and need for prostate surgery. To reduce risk of symptomatic progression of BPH, with doxazosin. Limitations of use: not for the prevention of prostate cancer.
5mg once daily. Reevaluate at 6 months, then periodically.
Not for use in children or women. Pregnant women (Cat.X) and those of childbearing potential should avoid handling crushed or broken tabs.
Increased risk of high-grade prostate cancer. Monitor prostate specific antigen (PSA) values; double PSA levels for comparison with normal ranges. Rule out prostate cancer and other urological disorders prior to treatment. Monitor for obstructive uropathy. Hepatic dysfunction.
Type II 5 alpha-reductase inhibitor.
Impotence, decreased libido or ejaculate volume, breast enlargement or tenderness, rash.